OBJECTIVES: N-myc downstream-regulated gene 1 (NDRG1), important in tumor growth and metastasis, has recently gained interest as a potential therapeutic target. Loss of NDRG1 expression is generally associated with poor clinical outcome in pancreatic cancer (PaCa) patients. As the NDRG1 gene possesses a large promoter CpG island, we sought to determine whether its repression is epigenetically mediated in PaCa cells. METHODS: Pancreatic cancer cells were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor trichostatin A. Promoter methylation was assessed by genomic bisulfite sequencing and by combined bisulfite restriction analyses. RESULTS: Treatment with 5-aza-2'-deoxycytidine and trichostatin A enhanced NDRG1 protein expression, implicating epigenetic regulation of NDRG1. However, there was no significant DNA methylation of the NDRG1 promoter CpG island, as determined by genomic bisulfite sequencing of HPAF-II cells. We further confirmed the lack of promoter methylation in 6 PaCa cell lines by combined bisulfite restriction analyses. CONCLUSIONS: These findings indicate that NDRG1 gene reactivation in PaCa cell lines by pharmacologic reversal of DNA methylation and histone deacetylation occurs via an indirect mechanism. This may occur via the altered expression of genes involved in the regulation of NDRG1 transcription or NDRG1 protein stability in PaCa cells.
OBJECTIVES:N-myc downstream-regulated gene 1 (NDRG1), important in tumor growth and metastasis, has recently gained interest as a potential therapeutic target. Loss of NDRG1 expression is generally associated with poor clinical outcome in pancreatic cancer (PaCa) patients. As the NDRG1 gene possesses a large promoter CpG island, we sought to determine whether its repression is epigenetically mediated in PaCa cells. METHODS:Pancreatic cancer cells were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor trichostatin A. Promoter methylation was assessed by genomic bisulfite sequencing and by combined bisulfite restriction analyses. RESULTS: Treatment with 5-aza-2'-deoxycytidine and trichostatin A enhanced NDRG1 protein expression, implicating epigenetic regulation of NDRG1. However, there was no significant DNA methylation of the NDRG1 promoter CpG island, as determined by genomic bisulfite sequencing of HPAF-II cells. We further confirmed the lack of promoter methylation in 6 PaCa cell lines by combined bisulfite restriction analyses. CONCLUSIONS: These findings indicate that NDRG1 gene reactivation in PaCa cell lines by pharmacologic reversal of DNA methylation and histone deacetylation occurs via an indirect mechanism. This may occur via the altered expression of genes involved in the regulation of NDRG1 transcription or NDRG1 protein stability in PaCa cells.
Authors: S Fukushige; F M Waldman; M Kimura; T Abe; T Furukawa; M Sunamura; M Kobari; A Horii Journal: Genes Chromosomes Cancer Date: 1997-07 Impact factor: 5.006
Authors: Markus Heidenblad; Eric F P M Schoenmakers; Tord Jonson; Ludmila Gorunova; Joris A Veltman; Ad Geurts van Kessel; Mattias Höglund Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: Marcelo Dos Santos; Ana Maria da Cunha Mercante; Fábio Daumas Nunes; Andréia Machado Leopoldino; Marcos Brasilino de Carvalho; Diana Gazito; Rossana Verónica Mendoza López; Paula Blandina Olga Chiappini; Paulo Bentes de Carvalho Neto; Erica Erina Fukuyama; Eloiza Helena Tajara; Iúri Drumond Louro; Adriana Madeira Álvares da Silva Journal: Mol Biol Rep Date: 2012-09-13 Impact factor: 2.316
Authors: Hiroki Takahashi; Monica C Chen; Hung Pham; Eliane Angst; Jonathan C King; Jenny Park; Ethan Y Brovman; Hideyuki Ishiguro; Diane M Harris; Howard A Reber; Oscar J Hines; Anna S Gukovskaya; Vay Liang W Go; Guido Eibl Journal: Biochim Biophys Acta Date: 2011-05-10